Business Context and Reporting Period
Company: Matinas Biopharma Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 19, 2018
Event: Entry into a Material Definitive Agreement regarding a private placement of Series B Convertible Preferred Stock.
Key Financial Metrics and Transaction Details
This filing details a capital raise rather than operational financial results. Key transaction metrics include:
- Securities Issued: Up to 8,000 shares of Series B Convertible Preferred Stock.
- Stated Value: $1,000 per share (Total potential gross proceeds: $8,000,000).
- Conversion Terms: Convertible into up to 16,000,000 shares of Common Stock at an initial conversion price of $0.50 per share.
- Dividend Shares: Up to 7,200,000 additional shares of Common Stock issuable upon payment of dividends.
- Placement Agent Fees: 7.0% cash fee, 1.0% non-accountable expense allowance, and up to $75,000 in legal fee reimbursements.
- Warrants Issued: 240,000 warrants to the placement agent exercisable at $0.75 per share.
Material Changes and Capital Structure
The filing announces a material change to the company's capital structure through the designation of Series B Preferred Stock. Key structural changes include:
- Ranking: Series B Preferred ranks junior to Series A Preferred Stock but senior to Common Stock regarding liquidation preferences.
- Dividend Structure: Dividends are payable in Common Stock at increasing rates: 10% at the 12-month anniversary, 15% at the 24-month anniversary, and 20% at the 36-month anniversary of the effective date.
- Automatic Conversion: Shares automatically convert into Common Stock upon the earlier of: (i) first FDA approval of a product candidate, (ii) the 36-month anniversary of the effective date, or (iii) consent of 50.1% of holders.
- Beneficial Ownership Limitation: Conversions are limited to prevent any holder from beneficially owning more than 4.99% of outstanding Common Stock (electable up to 9.99% with notice).
Outlook, Risks, and Management Commentary
Outlook and Closing: The offering is expected to close on June 21, 2018, subject to customary closing conditions. The company intends to use the proceeds for general corporate purposes, though specific allocation is not detailed in this text.
Risks and Contingencies:
- Closing Risk: The transaction is contingent on satisfying closing conditions; failure to close on a timely basis is a noted risk.
- Dilution: The issuance of up to 23,200,000 shares of Common Stock (conversion shares plus dividend shares) represents significant potential dilution to existing common shareholders.
- Liquidation Preference: In a liquidation event, Series B holders are paid after Series A holders but before Common Stock holders.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks detailed in the Form 10-K filed on March 16, 2018, and the prospectus supplements.
Investor Verification Checklist
- Verify the final closing date and actual gross proceeds raised against the expected $8,000,000.
- Review the full text of the Certificate of Designation (Exhibit 3.1) for specific anti-dilution adjustments and voting rights exceptions.
- Assess the impact of the 4.99% beneficial ownership limitation on the liquidity and convertibility of the preferred shares for major investors.
- Confirm the status of the Series A Preferred Stock to understand the full seniority hierarchy in a liquidation scenario.
- Monitor the company's progress toward FDA approval, as this triggers automatic conversion of the Series B Preferred.